Yotsukura Masaya, Asamura Hisao, Motoi Noriko, Kashima Jumpei, Yoshida Yukihiro, Nakagawa Kazuo, Shiraishi Kouya, Kohno Takashi, Yatabe Yasushi, Watanabe Shun-Ichi
Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Division of Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan.
J Thorac Oncol. 2021 Aug;16(8):1312-1320. doi: 10.1016/j.jtho.2021.04.007. Epub 2021 Apr 27.
The WHO classification of lung tumors defines adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) as cancers with no or limited histologic invasive components. The probability of patients with AIS or MIA being recurrence free for 5 years postoperatively has been found to be 100%. This study aimed to analyze the prognosis of patients with AIS or MIA after more than 5 postoperative years.
We reviewed the pathologic findings of 4768 patients who underwent resection for lung cancer between 1998 and 2010. Of these, 524 patients with curative resection for AIS (207 cases, 39.5%) and MIA (317 cases, 60.5%) were included. Postoperative recurrence, survival, and development of secondary primary lung cancer (SPLC) were analyzed.
Of the included patients, 342 (65.3%) were of female sex, 333 (63.5%) were nonsmokers, and 229 (43.7%) underwent sublobar resection. Average pathologic total tumor diameter was 15.2 plus or minus 5.5 mm. Median postoperative follow-up period was 100 months (range: 1-237). No recurrence of lung cancer was observed for either AIS or MIA cases. Estimated 10-year postoperative disease-specific survival rates were 100% and 100% (p = 0.72), and overall survival rates were 95.3% and 97.8% (p = 0.94) for AIS and MIA cases, respectively. Estimated incidence rates of metachronous SPLC at 10 years after surgery were 5.6% and 7.7% for AIS and MIA, respectively (p = 0.45), and these were not correlated with the EGFR mutation status.
Although the development of metachronous SPLC should be noted, the risk of recurrence is quite low at more than 5 years after resection of AIS and MIA. This finding strengthens the clinical value of distinguishing AIS and MIA from other adenocarcinomas of the lung.
世界卫生组织(WHO)的肺肿瘤分类将原位腺癌(AIS)和微浸润腺癌(MIA)定义为无组织学浸润成分或仅有有限组织学浸润成分的癌症。已发现AIS或MIA患者术后5年无复发的概率为100%。本研究旨在分析AIS或MIA患者术后5年以上的预后情况。
我们回顾了1998年至2010年间接受肺癌切除术的4768例患者的病理结果。其中,包括524例行AIS(207例,39.5%)和MIA(317例,60.5%)根治性切除术的患者。分析术后复发、生存情况以及异时性第二原发性肺癌(SPLC)的发生情况。
纳入的患者中,女性342例(65.3%),非吸烟者333例(63.5%),229例(43.7%)接受了肺叶以下切除。病理肿瘤总直径平均为15.2±5.5毫米。术后中位随访期为100个月(范围:1 - 237个月)。AIS和MIA病例均未观察到肺癌复发。AIS和MIA病例的术后10年疾病特异性生存率估计分别为100%和100%(p = 0.72),总生存率分别为95.3%和97.8%(p = 0.94)。术后10年AIS和MIA异时性SPLC的估计发病率分别为5.6%和7.7%(p = 0.45),且与表皮生长因子受体(EGFR)突变状态无关。
尽管应注意异时性SPLC的发生,但AIS和MIA切除术后5年以上复发风险相当低。这一发现强化了将AIS和MIA与其他肺腺癌区分开来的临床价值。